Effect of simvastatin on qualitative and quantitative changes of lipoprotein metabolism in CAPD patients.

No abstract is available for this paper.

• Publication year

  1992

• Venue

  Nephron

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  DOI 10.1159/000186993PMID 1436290
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Serum lipids and lipoproteins during continuous ambulatory peritoneal dialysis.

  2009cited by this paper
• Effect of simvastatin treatment on the dyslipoproteinemia in CAPD patients.

  1991cited by this paper
• Hyperlipoproteinemia in chronic renal failure: pathophysiological and therapeutic aspects.

  1991cited by this paper
• Effects of HMG-CoA reductase inhibitors in hypercholesterolemic patients on hemodialysis.

  1991cited by this paper
• Rapid apolipoprotein E phenotyping by immunofixation in agarose.

  1991cited by this paper
• Mortality and causes of death in patients with end-stage renal failure.

  1990cited by this paper
• Relation of serum lipoprotein(a) concentration and apolipoprotein(a) phenotype to coronary heart disease in patients with familial hypercholesterolemia.

  1990cited by this paper
• Lipoprotein (a): structure, properties and possible involvement in thrombogenesis and atherogenesis.

  1990cited by this paper
• Lipids in CAPD: a review.

  1990cited by this paper
• Clinical experience with lovastatin.

  1990cited by this paper
• Lp(a) lipoprotein concentration in serum of patients with heavy proteinuria of different origin.

  1989cited by this paper
• Gemfibrozil improves abnormalities of lipid metabolism in patients on continuous ambulatory peritoneal dialysis: the role of postheparin lipases in the metabolism of high-density lipoprotein subfractions.

  1989cited by this paper
• Tissue selectivity of the cholesterol-lowering agents lovastatin, simvastatin and pravastatin in rats in vivo.

  1989cited by this paper
• Lipoprotein and apolipoprotein losses during continuous ambulatory peritoneal dialysis.

  1989cited by this paper
• Metabolic effects of continuous ambulatory peritoneal dialysis.

  1989cited by this paper
• HMG CoA reductase inhibitors lower LDL cholesterol without reducing Lp(a) levels.

  1989cited by this paper
• Lipids, lipoproteins and apolipoproteins A-I and B and apolipoprotein losses in continuous ambulatory peritoneal dialysis.

  1989cited by this paper
• Effects of long-term CAPD on carbohydrate and lipid metabolism.

  1988cited by this paper
• Putative atherogenic factors in patients with chronic renal failure.

  1983cited by this paper
• Analysis of cardiovascular risk factors in chronic hemodialysis patients with special attention to the hyperlipoproteinemias.

  1983cited by this paper
• Sequential changes in serum lipids and their subfractions in patients receiving continuous ambulatory peritoneal dialysis.

  1983cited by this paper
• Improved assessment of plasma lipoprotein patterns. IV. Simple preparation of a lyophilized control serum containing intact human plasma lipoproteins.

  1982cited by this paper
• Biochemical studies on patients undergoing continuous ambulatory peritoneal dialysis

  1980cited by this paper
• Accelerated atherosclerosis in long-term dialysis and renal-transplant patients: fact or fiction?

  1980cited by this paper
• Acute muscular syndrome associated with administration of clofibrate.

  1968cited by this paper

• HMG CoA reductase inhibitors (statins) for dialysis patients.

  2013cites this paper
• HMG CoA reductase inhibitors (statins) for dialysis patients.

  2009cites this paper
• Therapeutic tools for dyslipidemia in peritoneal dialysis patients.

  2009cites this paper
• HMG CoA reductase inhibitors (statins) for dialysis patients.

  2009cites this paper
• Efecto del etofibrato de liberación sostenida en pacientes con concentraciones plasmáticas de lipoproteína(a) > 300 mg/l

  2003cites this paper
• The Effect of CAPD on the Lipid Profile of Pediatric Patients

  2000cites this paper
• Current status of prevention, diagnosis, and management of coronary artery disease in patients with kidney failure.

  2000cites this paper
• Application of Mupirocin Cream at the Catheter Exit Site Reduces Exit-Site Infections and Peritonitis in Peritoneal Dialysis Patients

  2000cites this paper
• Methods of literature review and synthesis.

  1998cites this paper
• [Dyslipidemias in renal diseases: pathogenesis and treatment].

  1998cites this paper
• Is Capd Atherogenic?

  1997cites this paper
• Effects of simvastatin and enalapril on serum lipoprotein concentrations and left ventricular mass in patients on dialysis. The Perfect Study Collaborative Group.

  1997cites this paper
• Treatment of Dyslipoproteinaemia in Diabetes Mellitus

  1996cites this paper
• Lipid-lowering therapy in patients with renal disease.

  1995cites this paper
• Lipid Parameters Including Lipoprotein (A) in Patients Undergoing CAPD and Hemodialysis

  1995cites this paper
• Reduction of intermediate density lipoprotein by pravastatin in hemo- and peritoneal dialysis patients.

  1995cites this paper
• Simvastatin. A reappraisal of its pharmacology and therapeutic efficacy in hypercholesterolaemia.

  1995cites this paper
• Lipoprotein(A): Physiologic Function, Association with Atherosclerosis, and Effects of Lipid-Lowering Drug Therapy

  1994cites this paper
• Characteristics of very early onset autosomal dominant polycystic kidney disease

  1993cites this paper
• The Effect of Simvastatin on Dyslipemia in Continuous Ambulatory Peritoneal Dialysis Patients

  1993cites this paper
• Treatment of hyperlipidemia in human renal disease.

  1993cites this paper
• Lipoprotein(a) in patients treated by continuous ambulatory peritoneal dialysis.

  1993cites this paper
• Disturbances of lipid metabolism in children with chronic renal failure

  1993cites this paper
• Lipoprotein metabolism and renal failure.

  1993cites this paper